DeutschNewstral
Article
bizjournals.com on 2015-01-02 22:19
Biotech investor explains why Juno Therapeutics won't be like Dendreon
Related news
- Juno Therapeutics CEO gets $450,000 bonus, recruits former Amgen, Dendreon researchersbizjournals.com
- Juno Therapeutics to open Bothell manufacturing facilitybizjournals.com
- Former Dendreon CEO's new biotech Alpine Immune Sciences raises $1.3Mbizjournals.com
- Why ex-Dendreon CEO's new biotech startup could succeed where Dendreon failedbizjournals.com
Celgene completes acquisition of Juno Therapeuticsseattletimes.com
Juno Therapeutics ends cancer drug trialKING 5- Biotech led venture-backed IPOs nationally in 2014 including Juno Therapeutics, 3 other Seattle biotechsbizjournals.com
- Juno Therapeutics suspends drug trial after new patient deathsseattletimes.com
- Biotech company Dendreon extends metro Atlanta leasebizjournals.com
- Juno Therapeutics will have some competition in the race to use immunotherapy to cure cancerbizjournals.com
- Juno Therapeutics plans commercial immunotherapy treatment launch by end of 2015bizjournals.com
- Juno Therapeutics stock soars as FDA approves new drug for non-Hodgkin lymphomabizjournals.com
- Seattle’s Juno Therapeutics ready for another round in war on cancerseattletimes.com
Seattle’s Juno Therapeutics ready for another round in war on cancer - Mon, 25 Sep 2017 PSTThe Spokesman-Review- Juno Therapeutics suspends drug trial after new patient deaths - Thu, 24 Nov 2016 PSTThe Spokesman-Review
- Juno Therapeutics plans Bothell manufacturing plantseattletimes.com
- Seattle biotech Silverback Therapeutics prices upsized IPOseattletimes.com
- Juno Therapeutics shopping for new headquarters in Seattlebizjournals.com
- Juno Therapeutics: Will cash burn hurt outlook after Monday's earnings?bizjournals.com
Juno Therapeutics gets $500K grant from state fundold.seattletimes.com